Semaglutide may help patients with bipolar disorder

Researchers at Griffith University suggest that GLP-1 drugs, known primarily for treating type 2 diabetes and obesity, may also benefit patients with bipolar disorder, which affects around 37 million people worldwide. New research points to a potential new application for semaglutide, though results require further verification.